



Powered by the Sharekhan 3R Research Philosophy

3R MATRIX	+	=	-
Right Sector (RS)	✓		✗
Right Quality (RQ)	✓		✗
Right Valuation (RV)	✓		✗

+ Positive = Neutral - Negative

What has changed in 3R MATRIX

	Old	New
RS	✓	↔
RQ	✓	↔
RV	✓	↔

Reco/View	Change
Reco: Buy	↔
CMP: Rs. 1,260	
Price Target: Rs. 1,450	↑


Upgrade ↔ Maintain ↓ Downgrade

Company details

Market cap:	Rs. 4,525 cr
52-week high/low:	Rs. 1,325 / 367
NSE volume:	1.7 lakh (No of shares)
BSE code:	541540
NSE code:	SOLARA
Free float:	2.0 cr (No of shares)

Shareholding (%)

Promoters	44.2
FII	28.2
DII	4.7
Others	22.9

Price chart**Price performance**

(%)	1m	3m	6m	12m
Absolute	15.1	36.0	130.8	189.8
Relative to Sensex	6.2	17.1	98.1	177.1

Sharekhan Research, Bloomberg

Solara Active Pharma Sciences**Growth Levers Intact****Pharmaceuticals****Sharekhan code: SOLARA****Company Update****Summary**

- We retain our Buy recommendation on Solara Active Pharma Sciences (Solara) with a revised PT of Rs. 1,450.
- Solara is witnessing strong demand traction across its business segments. It is well poised to grow as a leading 'global pure-play API company' given the strong customer relationships, expanding capacities and compliant business operations.
- Solara's emphasis on growing the CRAMS business bodes well, and would support the double-digit growth trajectory over the medium term.
- Solara's strong growth prospects, better earnings visibility, healthy balance sheet, and improving return ratios would support multiple expansion.

Solara Active Pharma Sciences (Solara) is witnessing strong demand traction across its business as immense opportunities lie ahead for pure play API companies. While there are cost differences between India and China, the deciding factor in the post-pandemic era would be supply chain reliability along with quality, as quality takes precedence over pricing factor. Consequently, established companies such as Solara, which are well placed will benefit from the situation, given the strong customer relations and compliant operations. Solara is targeting higher wallet share from existing clients and market share gains to grow its base business while new product launches which would unfold gradually, are expected to gain traction and support topline growth. Solara's overarching objective remains to bridge the industry gap by delivering value-based products that cater to customer requirements. In addition to API's, management's emphasis to grow the CRAMS business (through new client additions) bodes well, as it yields better margins as compared to the API business. The fruits of this are likely to accrue over the medium to long term. Solara has recently commissioned the Phase I (Ibuprofen plant with a capacity of 3600 kilo liters) of its Vizag facility which is likely to ramp up over the next four quarters, while the Phase II (multi product facility) is expected to be ready by end of FY2021. In order to reap the benefits of the backward integration, Solara shall be participating in the Government of India's PLI scheme, though in a small way. Further there could be some logistics issues in the ongoing quarter, due to the pandemic, however it is unlikely to have any material impact on the performance of the company. Overall, a strong demand outlook coupled with capacity expansion plans provides ample visibility on growth and would also help achieve the management's topline and EBITDA growth guidance of 30% and 40% respectively for FY2021.

Our Call

Retain Buy with a revised PT of Rs. 1,450: Solara is witnessing a strong demand environment for its business with the API business likely to benefit from the "China +1" strategy being adopted by global pharma companies. This coupled with the company's strong customer relationship and capabilities, new product launches, commissioning of Vizag plant (Phase I) would support growth and provides ample confidence on achieving the management's guidance of 30% topline growth and 40% EBITDA growth for FY2021. The company's emphasis on growing the CRAMS business bodes well, though it would bear fruits over the medium term and would support the double-digit growth trajectory. At CMP, the stock is trading at a valuation of 17.5x/13.5x its FY2022/FY2023E EPS. The company's strong growth prospects, better earnings visibility, healthy balance sheet, and improving return ratios would support multiple expansion. We retain our Buy recommendation on the stock with a revised PT of Rs. 1,450.

Key risk

Any adverse change in the regulatory landscape can impact earnings prospects; 2) adverse foreign exchange movement.

Valuation


Particulars	FY2019	FY2020	FY2021E	FY2022E	FY2023E	Rs cr
Total Sales	1386.7	1321.8	1705.1	2015.3	2420.1	
EBIDTA	220.8	259.4	405.8	473.6	576.0	
OPM (%)	15.9	19.6	23.8	23.5	23.8	
Reported PAT	67.1	114.5	215.4	255.1	330.1	
EPS (Rs)	18.9	32.3	60.7	71.9	93.1	
PER (x)	66.6	39.0	20.7	17.5	13.5	
EV/Ebitda (x)	21.8	19.3	12.3	10.3	8.1	
P/BV (x)	4.7	4.1	3.4	2.9	2.4	
ROCE (%)	9.9	10.8	16.3	16.8	18.2	
RONW (%)	7.0	10.5	16.6	16.5	17.8	

Source: Company; Sharekhan estimates

Huge potential lies ahead in the API space; Solara witnesses strong demand traction


The API space offers immense growth potential for companies as substantial opportunities have emerged amidst uncertain times of the pandemic. In these testing and challenging times, pharmaceutical companies globally have confronted challenges with respect to supply disruption as dependence on China was far higher. In the post pandemic era, supply reliability and quality are factors that have taken precedence over pricing, and pharma companies the world over are looking for these points while selecting their partners.

Revenue share trends - US and Europe (% of sales)



Source: Company; Sharekhan Estimates

Revenue Mix - Geographywise (% of FY2020 sales)



Source: Company; Sharekhan Estimates


Established players such as Solara are likely to benefit from the situation as its “China +1” strategy gains momentum. Also the Indian companies such as Solara have the required capabilities and bandwidth to cater to the requirements of global companies. Further, for the quarter ending September 2020, Solara has managed to gain wallet share from its existing customers. Also the company has gained market share in select pockets, while demand for base products was strong. Solara is witnessing strong demand outlook across geographies for its products. The base business has performed well and strong growth momentum is expected to sustain going ahead as well. The company has a portfolio of 40+ products, which is well diversified. Moreover, the company has strong relationship with its customers, which would enable it to garner a higher wallet share. These would drive growth in the base business. Moreover, new products/recent launches are fast gaining traction, which in turn would support topline growth. In addition to this, Solara has a strong product pipeline, which would enable it to maintain the growth momentum. Overall we expect the company to benefit from a structural shift in global supply chains, which are likely to favour Indian API companies, with a significant potential for market share gains. This coupled with strong growth in the base business and new product launches would be the key growth drivers for the API segment. The API segment revenues are expected to clock a strong double digit 22% CAGR over FY2020 to Fy2023.

Capacity Expansion plans provides visibility on topline growth:

Solara is in the midst of a capacity expansion plan where it has commissioned the phase 1 of its Vizag capacity expansion in the quarter ending September 2020 and expects production to ramp up fully and achieve the optimum levels over the next four quarters. Phase I is an Ibuprofen facility with 3,600 kilo litre capacity. To consistently support growth momentum, Solara is also setting up phase 2 at Vizag, which is likely to be ready by FY2021. Phase II would be a multi product facility. Incremental capacities going on stream would support topline growth for the company. The incremental capacities going on stream coupled with a buoyant demand environment would support the topline growth. In the quarter ending September 2020, the company had guided for a 30% topline growth for FY2021 and basis the above positives, the management seems quite confident of achieving the target growth.


Financials in charts

Sales Trends (Rs Cr)




Source: Company, Sharekhan Research

Operating Profit - PAT Trends




Source: Company, Sharekhan Research

Margins on an improving trend




Source: Company, Sharekhan Research

Debt : Equity (x)




Source: Company, Sharekhan Research

Return ratio to improve



Source: Company, Sharekhan Research

ROCE (%)



Source: Company, Sharekhan Research

Outlook and Valuation

■ Sector View – Growth momentum to improve

Indian pharmaceutical companies are better placed to harness opportunities and report healthy growth going ahead. Indian companies are among the most competitive ones globally and hold a sizeable market share in most developed as well as other markets. Moreover, other factors such as easing of pricing pressures (especially in the US generics market), rise in product approvals, and plant resolutions by the USFDA coupled with strong growth prospects in domestic markets and emerging opportunities in the API space would be key growth drivers. This would be complemented by strong capabilities developed by Indian companies (leading to a shift towards complex molecules and biosimilars) and commissioning of expanded capacities by select players over the medium term. Collectively, this indicates a strong growth potential going ahead for pharma companies.


■ Company Outlook – Strong growth prospects

There are immense opportunities ahead for pure play API companies such as Solara to grow going ahead. Excess dependence on China has led to dual source qualification. Solara has initiated efforts to backward integrate KSMs (Key Starting Materials) of its key APIs as well as collaborate with local manufacturers to reduce its dependence on China. While there are cost differences between India and China, the deciding factor in a post-pandemic era will be supply chain reliability along with quality, as it has taken precedence over pricing. Solara's overarching objective remains to bridge the industry gap by delivering value-based products that cater to customer requirements. The company is well poised to grow as a leading 'global pure-play API company' focusing on highly compliant business operations. In addition to this, the management's emphasis to grow the CRAMS business bodes well, as it yields better margins as compared to the API business. The fruits of this are likely to accrue over the long term.

■ Valuation – Retain Buy with a revised PT of Rs. 1,450

Solara is witnessing a strong demand environment for its business going ahead. The API space is witnessing strong and widespread growth opportunities. This coupled with the company's strong customer relationship and capabilities, new product launches, provide ample growth visibility going ahead. Further, the commissioning of Vizag plant would support the growth and provides ample confidence on achieving the managements target of 30% topline growth and 40% EBITDA growth for FY2021. The company's emphasis on growing the CRAMS business bodes well, though it would bear fruits over the medium term and would support the double-digit growth trajectory. At CMP, the stock is trading at a valuation of 17.5x/13.5x its FY2022/FY2023E EPS. The company's strong growth prospects, better earnings visibility, healthy balance sheet, and improving return ratios would support multiple expansion. We retain our Buy recommendation on the stock with a revised PT of Rs. 1,450.

One year forward PE chart



Source: Sharekhan Research

Peer Comparison

Particulars	CMP (Rs / Share)	O/S Shares (Cr)	MCAP (Rs Cr)	P/E (x)			EV/EBIDTA (x)			RoE (%)		
				FY20	FY21E	FY22E	FY20	FY21E	FY22E	FY20	FY21E	FY22E
Solara	1260	3.5	4525	39.0	20.7	17.5	19.3	12.3	10.3	10.5	16.6	16.5
Divis Laboratories	3,689	26.5	97,929	75.6	51.0	39.1	50.8	34.6	26.9	17.7	21.7	22.8

Source: Company, Sharekhan estimates

About company

Solara is a customer-oriented API manufacturer. The company has legacy of over three decades and has its origins traced from the API expertise of Strides Shasun Limited and the technical know-how of human API business of one of the leading pharma companies. Solara has 200+ scientists, six API manufacturing facilities armed with global approvals, and two dedicated R&D facilities. Solara offers a basket of diversified, high-value commercial APIs, and contract manufacturing services in over 75 countries, covering the entire life cycle of a new chemical entity, from pre-clinical and clinical phases to validation and commercial supply, while fully complying with domestic and international guidance. The company is focusing on highly compliant business operations and customer support. The company's six API manufacturing facilities are located in Ambernath (near Mumbai), Cuddalore, Mangalore, Mysore, Puducherry, and Visakhapatnam with a capacity of over 2,000 kilo litre.

Investment theme

The pandemic has opened up immense opportunities for the Indian pharmaceutical sector. Excess dependence on China has led to dual source qualification, while stocking of essential medicines has led to increased demand in the short to medium term. Solara has initiated efforts to backward integrate the KSMs of its key APIs as well as collaborate with local manufacturers to reduce its dependence on China. While there are cost differences between India and China, the deciding factor in a post COVID-19 world will be supply chain reliability, as it has taken precedence over pricing. Solara's overarching objective remains to bridge the industry gap by delivering value-based products that cater to customer requirements. In addition to this, management's emphasis to grow the CRAMS business bodes well, as it yields better margins as compared to the API business. The fruits of this are likely to accrue over the long term.

Key Risks

Any adverse change in the regulatory landscape can impact earnings prospects; 2) adverse foreign exchange movement.

Additional Data

Key management personnel

Mr Deepak Vaidya	Chairman & Non Executive Director
Mr Bharat Sesha	Managing Director & Chief Executive Officer
Mr Hariharan S	Executive Director - Finance
Mr. Subash Anand	Chief Financial officer

Source: Company Website

Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	TPG GROWTH IV SF PTE. LTD.	4.09
2	SBI MAGNUM MIDCAP FUND	3.57
3	IMF Holdings	3.01
4	Chayadeep ventures	2.81
5	HBM Healthcare investments	1.58
6	Kotak Mahindra Asset Management Co	0.61
7	Devicam Capital LLP	0.42
8	Dimensional Fund Advisors	0.27
9	Agnus Holdings Pvt Ltd	0.2
10	State Street Corp	0.19

Source: Bloomberg

as on Sep 13, 2020

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Understanding the Sharekhan 3R Matrix

Right Sector	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
Right Quality	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/weak realisation environment resulting in margin pressure and deteriorating balance sheet
Right Valuation	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research

Know more about our products and services

For Private Circulation only

Disclaimer: This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst further certifies that neither he or its associates or his relatives has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Limited or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: compliance@sharekhan.com;

For any queries or grievances kindly email igc@sharekhan.com or contact: myaccount@sharekhan.com

Registered Office: Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. KanjurMarg Railway Station, KanjurMarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com; Investment in securities market are subject to market risks, read all the related documents carefully before investing.